Alterity Therapeutics (ASX: ATH) is a clinical-stage biotechnology company founded in 2004, with headquarters in Melbourne, Australia, and San Francisco, California. The company is focused on developing disease-modifying treatments for neurodegenerative diseases, with a particular emphasis on Parkinsonian disorders. Its lead asset, ATH434, has demonstrated the potential to significantly slow the progression of MSA, a rare and rapidly progressive disease. The company also has a broad drug discovery platform generating patentable chemical compounds to address the underlying pathologies of neurological diseases. Alterity aims to provide effective treatments for patients suffering from MSA and Parkinson’s disease, where current options are limited. In addition to its operations in Australia and the US, Alterity engages with global markets for its research and clinical activities. Currently, the company’s shares are trading at 1.1 cents per share.
Multiple System Atrophy (MSA) is a rare neurodegenerative disorder characterised by the progressive deterioration of the nervous system, leading to problems with movement, balance, and autonomic functions. ATH434 has shown promising results in clinical trials, demonstrating a significant slowing of clinical progression and a favourable safety profile. In the ATH434-201 Phase 2 clinical trial, the drug demonstrated a 48% slowing of clinical progression at the 50 mg dose, as measured by the Unified MSA Rating Scale (UMSARS), which assesses activities of daily living in MSA patients. These promising results have reinforced Alterity’s confidence in ATH434’s potential to make a meaningful impact in treating MSA and other Parkinsonian disorders.
The capital raised was strongly supported by both domestic and international institutional investors, demonstrating confidence in Alterity’s strategic direction and the promise of ATH434. The placement involved a wide range of sophisticated and professional investors, including both Australian and global institutions, who see the potential of Alterity’s pipeline and its lead candidate in the treatment of neurodegenerative diseases. These investors have committed to backing Alterity’s continued development, which is essential to bring ATH434 closer to market.
The funds raised from this placement will provide Alterity with the necessary resources to advance ATH434 through regulatory and clinical development, with a particular focus on MSA and Parkinson’s disease. Additionally, the funds will support the company’s ongoing research and discovery efforts to develop novel compounds for neurodegenerative diseases. The company plans to engage with the U.S. Food and Drug Administration to discuss the regulatory path forward for ATH434, with the goal of accelerating its development and bringing it to market for patients with MSA as soon as possible.
Parkinsonian disorders, including MSA and Parkinson’s disease, represent a significant unmet medical need, with limited effective treatments currently available. MSA is a rare condition, but it is rapidly progressive and debilitating, with most patients requiring extensive care as the disease advances. The market for treatments for Parkinsonian disorders is substantial, and ATH434 has the potential to become a first-in-class therapy for MSA and Parkinson’s disease. The strong clinical data and the company’s commitment to accelerating ATH434’s development position Alterity to make a significant impact in the treatment of these devastating diseases.
Alterity Therapeutics is dedicated to developing disease-modifying therapies for a range of neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, and MSA. The company’s research and drug discovery platforms are focused on developing novel compounds that can address the underlying causes of these diseases, offering hope for patients with limited treatment options. The capital raised will enable Alterity to continue its commitment to advancing therapies that could change the future of neurodegenerative disease treatment and significantly grow the company.
Chifley Tower, 2 Chifley Square,
Sydney NSW 2000
1300 854 151
© 2023 KOSEC | Kodari Securities Pty Ltd | ABN 90 147 963 755 | FSG | Terms & Conditions | Disclaimer & Legal
© 2023 KOSEC | Kodari Securities Pty Ltd
ABN 90 147 963 755
KOSEC - Kodari Securities does not provide any investment advice, nor is anything mentioned an offer to sell, or a solicitation of an offer to buy any security or other instrument. Anything discussed is for informational purposes only and does not address the circumstances or needs of any particular individual or entity. Investing in the stock market is high risk. Under no circumstances should investments be based solely on the information provided. We do not guarantee the security or completeness of information on this website and are not held liable. Kodari Securities PTY Ltd trading as KOSEC is a corporate authorized representative (AFSL no.246638) which is regulated by the Australian securities and investment commission (ASIC).
